Alexey Nazarov
Alexey Nazarov
Verified email at
Cited by
Cited by
Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity
Z Adhireksan, GE Davey, P Campomanes, M Groessl, CM Clavel, H Yu, ...
Nature communications 5 (1), 1-13, 2014
Organometallic ruthenium (II) arene compounds with antiangiogenic activity
P Nowak-Sliwinska, JR van Beijnum, A Casini, AA Nazarov, G Wagnieres, ...
Journal of medicinal chemistry 54 (11), 3895-3902, 2011
Opening the lid on piano-stool complexes: an account of ruthenium (II)–arene complexes with medicinal applications
AA Nazarov, CG Hartinger, PJ Dyson
Journal of Organometallic Chemistry 751, 251-260, 2014
Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium−Arene Compounds
MG Mendoza-Ferri, CG Hartinger, RE Eichinger, N Stolyarova, K Severin, ...
Organometallics 27 (11), 2405-2407, 2008
Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity
MG Mendoza-Ferri, CG Hartinger, MA Mendoza, M Groessl, AE Egger, ...
Journal of medicinal chemistry 52 (4), 916-925, 2009
Carbohydrate-metal complexes and their potential as anticancer agents
CG Hartinger, AA Nazarov, SM Ashraf, PJ Dyson, BK Keppler
Current medicinal chemistry 15 (25), 2574-2591, 2008
Metal-based inhibition of poly (ADP-ribose) polymerase− the guardian angel of DNA
F Mendes, M Groessl, AA Nazarov, YO Tsybin, G Sava, I Santos, ...
Journal of medicinal chemistry 54 (7), 2196-2206, 2011
In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate‐based ligands
I Berger, M Hanif, AA Nazarov, CG Hartinger, RO John, ML Kuznetsov, ...
Chemistry–A European Journal 14 (29), 9046-9057, 2008
Maltol‐Derived Ruthenium–Cymene Complexes with Tumor Inhibiting Properties: The Impact of Ligand–Metal Bond Stability on Anticancer Activity In Vitro
W Kandioller, CG Hartinger, AA Nazarov, C Bartel, M Skocic, MA Jakupec, ...
Chemistry–A European Journal 15 (45), 12283-12291, 2009
Influence of the Arene Ligand, the Number and Type of Metal Centers, and the Leaving Group on the in Vitro Antitumor Activity of Polynuclear Organometallic …
MG Mendoza-Ferri, CG Hartinger, AA Nazarov, RE Eichinger, ...
Organometallics 28 (21), 6260-6265, 2009
Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules
M Hanif, AA Nazarov, A Legin, M Groessl, VB Arion, MA Jakupec, ...
Chemical Communications 48 (10), 1475-1477, 2012
Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta
AK Renfrew, AD Phillips, AE Egger, CG Hartinger, SS Bosquain, ...
Organometallics 28 (4), 1165-1172, 2009
From Pyrone to Thiopyrone Ligands− Rendering Maltol-Derived Ruthenium (II)− Arene Complexes That Are Anticancer Active in Vitro
W Kandioller, CG Hartinger, AA Nazarov, ML Kuznetsov, RO John, ...
Organometallics 28 (15), 4249-4251, 2009
Osmium (II)–versus ruthenium (II)–arene carbohydrate-based anticancer compounds: similarities and differences
M Hanif, AA Nazarov, CG Hartinger, W Kandioller, MA Jakupec, VB Arion, ...
Dalton Transactions 39 (31), 7345-7352, 2010
DNA interactions of dinuclear RuII arene antitumor complexes in cell-free media
O Nováková, AA Nazarov, CG Hartinger, BK Keppler, V Brabec
Biochemical pharmacology 77 (3), 364-374, 2009
Protein ruthenation and DNA alkylation: chlorambucil-functionalized RAPTA complexes and their anticancer activity
AA Nazarov, SM Meier, O Zava, YN Nosova, ER Milaeva, CG Hartinger, ...
Dalton Transactions 44 (8), 3614-3623, 2015
Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety
W Kandioller, CG Hartinger, AA Nazarov, J Kasser, R John, MA Jakupec, ...
Journal of Organometallic Chemistry 694 (6), 922-929, 2009
Organometallic antitumour agents with alternative modes of action
A Casini, CG Hartinger, AA Nazarov, PJ Dyson
Medicinal Organometallic Chemistry, 57-80, 2010
A glucose derivative as natural alternative to the cyclohexane‐1, 2‐diamine ligand in the anticancer drug oxaliplatin?
I Berger, AA Nazarov, CG Hartinger, M Groessl, SM Valiahdi, MA Jakupec, ...
ChemMedChem: Chemistry Enabling Drug Discovery 2 (4), 505-514, 2007
From hydrolytically labile to hydrolytically stable RuII–arene anticancer complexes with carbohydrate-derived co-ligands
M Hanif, SM Meier, W Kandioller, A Bytzek, M Hejl, CG Hartinger, ...
Journal of inorganic biochemistry 105 (2), 224-231, 2011
The system can't perform the operation now. Try again later.
Articles 1–20